Overview SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors Status: RECRUITING Trial end date: 2025-04-01 Target enrollment: Participant gender: Summary Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.Phase: NA Details Lead Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd.